- Conference Call and Webcast to Follow at 5:00 p.m. EDT/ 2:00 p.m.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 11, 2018--
Inc. (NASDAQ: EXEL) announced today that its first quarter 2018
financial results will be released on Wednesday, May 2, 2018 after the
markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management
will host a conference call and webcast to discuss the results and
provide a general business update. Access to the event is available via
the Internet from the company’s website.
To access the webcast link, log onto www.exelixis.com
and proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s website at
least 15 minutes prior to the conference call to ensure adequate time
for any software download that may be required to listen to the webcast.
Alternatively, please call 855-793-2457 (domestic) or 631-485-4921
(international) and provide the conference call passcode 7895176 to join
A telephone replay will be available until 8:30 p.m. EDT on May 4, 2018.
Access numbers for the telephone replay are: 855-859-2056 (domestic) and
404-537-3406 (international); the passcode is 7895176. A webcast replay
will also be archived on www.exelixis.com
for one year.
Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in model
genetic systems, we established a broad drug discovery and development
platform that has served as the foundation for our continued efforts to
bring new cancer therapies to patients in need. We discovered our lead
compounds, cabozantinib and cobimetinib, and advanced them into clinical
development before entering into partnerships with leading
biopharmaceutical companies in our efforts to bring these medicines to
patients globally. We are steadfast in our commitment to prudently
reinvest in our business to maximize the potential of our pipeline. We
intend to supplement our existing therapeutic assets with targeted
business development activities and internal drug discovery – all to
deliver the next generation of Exelixis medicines and help patients
recover stronger and live longer. Exelixis recently earned a spot on
Deloitte’s Technology Fast 500 list, a yearly award program honoring the
500 fastest-growing companies over the past four years. For more
information about Exelixis, please visit www.exelixis.com,
follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Exelixis and the Exelixis logo are registered U.S. trademarks.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180411006318/en/
Source: Exelixis, Inc.
Susan Hubbard, 650-837-8194
Vice President, Public Affairs & Investor Relations